Fast Market Research announces the availability of the new Global Markets Direct report, "Programmed Cell Death Protein 1 - Pipeline Review, H2 2016", on their comprehensive research portal
Boston, MA -- (SBWIRE) -- 11/08/2016 -- Global Markets Direct's, 'Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) - Pipeline Review, H2 2016', provides in depth analysis on Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted pipeline therapeutics.
The report provides comprehensive information on the Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics development and features dormant and discontinued projects.
Get More Details on this Report and a Full Table of Contents at Programmed Cell Death Protein 1 - Pipeline Review, H2 2016
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
*Certain sections in the report may be removed or altered based on the availability and relevance of data.
*Updated report will be delivered in 48 hours of order confirmation.
-The report provides a snapshot of the global therapeutic landscape for Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1)
-The report reviews Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
-The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
-The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
-The report reviews key players involved in Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics and enlists all their major and minor projects
-The report assesses Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
-The report summarizes all the dormant and discontinued pipeline projects
-The report reviews latest news and deals related to Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) targeted therapeutics
Reasons to Get This Report
-Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
-Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
-Identify and understand the targeted therapy areas and indications for Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1)
-Identify the use of drugs for target identification and drug repurposing
-Identify potential new clients or partners in the target demographic
-Develop strategic initiatives by understanding the focus areas of leading companies
-Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
-Devise corrective measures for pipeline projects by understanding Programmed Cell Death Protein 1 (PD1 or CD279 or PDCD1) development landscape
-Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned in this Report: Aduro BioTech, Inc., Agenus, Inc., Aurigene Discovery Technologies Limited, BeiGene, Ltd., Beijing Hanmi Pharmaceutical Co., Ltd., BIOCAD, Cellular Biomedicine Group, Inc., CytomX Therapeutics, Inc., Eli Lilly and Company, Enumeral Biomedical Holdings, Inc., Immunovo BV, Jiangsu Hengrui Medicine Co., Ltd., Jounce Therapeutics, Inc., Les Laboratoires Servier SAS, MacroGenics, Inc., MD Biosciences GmbH, MedImmune, LLC, Merck & Co., Inc., Molecular Partners AG, Novartis AG, Ono Pharmaceutical Co., Ltd., Pfizer Inc., PharmaEssentia Corporation, Pieris Pharmaceuticals Inc, Regeneron Pharmaceuticals Inc, Sutro Biopharma, Inc., Symphogen A/S, Tasly Pharmaceutical Group Co., Ltd., Tesaro, Inc., Theravectys SA, Tikcro Technologies, Ltd., Vyriad, Xencor, Inc.
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Drug Pipeline research reports at Fast Market Research
You may also be interested in these related reports:
-Programmed Cell Death Protein 1 (CD279 or Systemic Lupus Erythematosus Susceptibility 2 or PD1) - Pipeline Review, H1 2016
-Programmed Cell Death 1 Ligand 1 (PD-L1 or B7 Homolog 1 or B7-H1 or CD274) - Pipeline Review, H1 2016
-Tyrosine Protein Kinase Lck (Leukocyte C Terminal Src Kinase or Protein YT16 or Proto Oncogene Lck or T Cell Specific Protein Tyrosine Kinase or Lymphocyte Cell Specific Protein Tyrosine Kinase or p56 LCK or LCK or EC 126.96.36.199) - Pipeline Review, H2 2016
-Hypoxia Inducible Factor 1 Alpha - Pipeline Review, H2 2016
-Tyrosine Protein Kinase Receptor UFO (AXL Oncogene or AXL or EC 188.8.131.52) - Pipeline Review, H2 2016